PDCD1 and neoplasm: More importantly, PTPN11 inhibitors combined with immunotherapies, such as anti-PD-1/L1, would reverse immunosuppression in the tumor microenvironment (TME) and potentiate the systemic antitumor effect in NSCLC cancer (213, 214).